Navigation Links
BioVex to Present at the UBS Global Life Sciences Conference
Date:9/18/2008

WOBURN, Mass., Sept. 18 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced that Philip Astley-Sparke, President and CEO, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 25th at 8:00 A.M. The conference is being held at the Grand Hyatt New York in New York, NY.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEXGM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEXGM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.

BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Earlier this year, the Company announced that the FDA approved the design of a single, pivotal Phase III clinical trial evaluating OncoVEXGM-CSF in previously treated patients with metastatic melanoma under the Special Protocol Assessment (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. BioVex intends to begin its Phase III trial for OncoVEXGM-CSF in melanoma in the first quarter of 2009.

BioVex recently announced that the
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
3. BioVex Closes Second Round of Series E Financing
4. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
5. Avicena Group to Present at Noble Financial Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CEL-SCI to Present at the Noble Financial Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , ... July 27, 2015 , ... ... of the Biophotonics industry.The report provides a basic overview of the industry including ... for the international markets including development trends, competitive landscape analysis, and key regions ...
(Date:7/27/2015)... 27, 2015 Research presented at the 2015 ... on the studies that led to a fingerprick Ebola ... this disease to receive approval from the World Health ... Ebola,s grip on West Africa ... healthcare workers to isolate and treat these patients much ...
(Date:7/27/2015)... YORK , July 27, 2015 Junto ... and startups share information and develop new technology solutions, ... Sachs Policy Group (SPG), a leader in health care ... will now engage in a collaborative innovation process while, ... the latest trends in public policy, health care finance ...
(Date:7/25/2015)... ... July 25, 2015 , ... Technology leader Anton ... checks and adjusts the surface temperature of the measuring prism. This is required ... data traceability and documentation are key requirements. It is likely that no refractometer ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4It’s T-Time for Refractometers: On-site Temperature Check Now Available 2
... , , ... , The ribonuclease protection assay (RPA) ... mRNA species. The assay was made possible,by the discovery and characterization ... properties that,make them well suited for the preparation of highly specific,hybridization ...
... , , , Product Literature Center Articles , ... , , ... Expression Patterns with Improved Tools for Target Amplification , , ... with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System , ...
... , , , ... , Like all components of a PCR or RT-PCR assay, ... DNA, RNA, nucleases,or a variety of microorganisms. These contaminants,often contribute to suboptimal amplification ... , , Roche Applied Sciences LightCycler Kits ...
Cached Biology Technology:RNase Protection Assay (RPA),Using DIG-Labeled RNA Probes 2Roche Diagnostics Corporation 2Roche Diagnostics Corporation 3Roche Diagnostics Corporation 4Roche Diagnostics Corporation 5Enjoy a Greater Sense of Security,with PCR-Grade Water 2
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... Molecular and Cell Biology (IMCB) and the Singapore Bioimaging ... controls both obesity and atherosclerosis. The team demonstrated, for ... gene were resistant to weight gain and atherosclerosis via ... its downstream signalling molecule mTor. These groundbreaking findings were ...
... Function and significance of the biological clocks in polar ... Institute entitled PolarTime starting July 1st, 2012. It is ... Helmholtz Association. PolarTime, coordinated by the Alfred Wegener Institute ... up to five years with approximately three million euros ...
... in German . , One bit of ... about 3 million magnetic atoms. Researchers from Karlsruhe, Strasbourg, and ... per molecule. By an electric pulse, the metal-organic molecule can ... low-conductive, non-magnetic state. This novel correlation for molecules is now ...
Cached Biology News:Groundbreaking discovery of mechanism that controls obesity, atherosclerosis 2Just a question of time? 2Just a question of time? 3Nature: Molecule changes magnetism and conductance 2
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Tachykinin (H-2)...
Human GATA-2 Affinity Purified Polyclonal Ab...
Biology Products: